Physician profile
Shannon E Leigh
NPI 1033431812
$1,511.78
in general payments reported to CMS, 2019-2025
19 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $387 · 2023: $673 · 2024: $98.17 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $215.66 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.39 | 2021-2023 | Lifevest |
| Amgen INC. | $183.36 | 2021-2025 | Repatha, Repatha |
| Medtronic, INC. | $128.69 | 2023 | Onyx Frontier |
| Abiomed | $125.67 | 2025 | |
| Janssen Pharmaceuticals, INC | $120.76 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $112.75 | 2021 | |
| Impulse Dynamics (USA) INC. | $80.95 | 2023-2024 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $69.62 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $53.99 | 2022-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $41.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $36.83 | 2023 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $33.08 | 2022 | |
| Heartflow, INC. | $24.63 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals, LTD. | $23.40 | 2023 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $19.24 | 2023 | Assure Wcd |
| Bardy Diagnostics, INC. | $19.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.25 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Leigh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.